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THE EFFECT OF STATIN EXPOSURE ON CLONAL PANCREATIC BETA 
CELLS (INS-1) METABOLISM AND INSULIN SECRETION 
KEANU SAO 
ABSTRACT 
 Objective: To investigate the effects of statin exposure on insulin secretion and 
metabolism in pancreatic beta cells in order to determine possible mechanisms that may 
contribute to the increased risk of developing Type 2 Diabetes that has been associated 
with taking statins. 
 Methods: Simvastatin and Pitavastatin were prepared to resemble the intracellular 
active form of the compound by converting the lactone, when present to a carboxyl group. 
These statins were then incubated at varying concentrations (0-200 nM) with clonal 
pancreatic β-cells (INS-1) for variable amounts of time (24-72 hours). Glucose-stimulated 
insulin secretion was measured from INS-1 cells cultured at low (4 mM) and high (11 mM) 
glucose with and without statin incubation. Results were measured using a homogenous 
time-resolved fluorescence (HTRF) insulin assay kit (Cisbio). The effect of statins on INS-
1 cellular metabolism was determined by measuring oxygen consumption rate using a 
Seahorse XFe96 analyzer (Agilent Technologies). Statin effects on intracellular Ca2+ 
([Ca2+]i) was examined in INS-1 cells cultured on glass bottom dishes loaded with the 




 Results: Simvastatin significantly inhibited GSIS and depleted insulin content in a 
dose-dependent manner (25-200 nM) after 72-hour exposure. However, when normalized 
for insulin content, inhibition was not observed. In contrast, pitavastatin did not affect 
GSIS, but did decrease insulin content in a dose-dependent manner (25-200 nM). At both 
high and low glucose, simvastatin (200 nM) increased the frequency and amplitude of 
intracellular calcium ([Ca2+]) oscillations at 1, 3, and 12 mM glucose. Furthermore, 
simvastatin increased mitochondrial respiration at low glucose, in cells exposed to the 
highest dose of simvastatin (200 nM). 
 Conclusion: Inhibition of GSIS by simvastatin and not pitavastatin, confirmed 
previous results from our lab that indicate that statins may have differential mechanistic 
effects on β-cells. Furthermore, intracellular calcium ([Ca2+])i imaging revealed that cells 
exposed to simvastatin (200 nM) had increased oscillation frequency and amplitude at 
basal (1, 3 mM) and high (12 mM) glucose conditions, indicating a potential difference in 
basal insulin secretion that may contribute to hyperinsulinemia. Lastly, mitochondrial 
respiration at low glucose increased in cells exposed to the highest dose of simvastatin (200 
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Atherosclerotic Cardiovascular Disease 
Cardiovascular disease (CVD) is a non-communicable disease that has negatively 
contributed to overall public health in both industrialized and developing countries. CVD 
is a group of disorders, such as coronary heart disease, peripheral artery disease, congestive 
heart failure, and stroke that affect the heart and blood vessels. According to the CDC, 
within the United States, about 647,000 Americans die from heart disease each year, which 
is about 1 in every 4 deaths. Globally, an estimated 17.9 million people died from CVD’s 
in 2016, representing about 31% of all global deaths (WHO 2017). In the US, an estimated 
92.1 million adults have at least 1 type of CVD, and it is predicted that by 2030, around 
44% of the US adult population is expected to have some type of CVD (Moonesinghe et 
al., 2019). Atherosclerosis is the main cause of morbidity and mortality associated with 
CVD, leading to the buildup of plaque inside of arteries.  
Atherosclerosis is a chronic inflammatory condition characterized by the 
accumulation of lipids and fibrous elements in the large arteries. Previous studies have 
shown that high levels of low-density lipoprotein (LDL) cholesterol and apolipoprotein B 
(ApoB) 100, are directly associated with risk for atherosclerotic cardiovascular disease 
(ASCVD). These two substrates promote an inflammatory response in which circulating 
monocytes adhere to endothelial cells, resulting in the expression of adhesion molecules 
and selectins; thus, increasing the migration of monocytes to the sub-endothelial space 
(Barquera et al., 2015). Internalization of ApoB containing lipoproteins by macrophages 
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promotes conversion of monocytes to foamy macrophages that are rich in both free fatty 
acids and cholesterol esters and result in the proliferation of smooth muscle cells, which 
provide a fibrous barrier caused by the production of extracellular matrix. Foamy 
macrophages release chemoattractants that stimulate infiltration into the arterial walls. 
Over time, processes such as increased macrophage apoptosis, decreased extracellular 
matrix production, and smooth muscle cell death can result in the buildup of atherosclerotic 
plaques. These vulnerable plaques are prone to rupture and can lead to ischemic ASCVE 
(Linton et al., 2019).  
Statins 
 Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, are a class of lipid-lowering medications prescribed to individuals in 
order to help lower blood cholesterol levels, thus potentially decreasing the frequency of 
heart attacks due to ASCVE. Statins were first discovered by Akira Endo in 1976 and 
approved by the FDA for clinical use as an LDL-cholesterol lowering agent in 1987 (Endo 
2010). Statins target hepatocytes and competitively bind and inhibit HMG-CoA reductase, 
an enzyme whose primary function is to convert HMG-CoA to mevalonic acid, which is 
the rate-limiting enzyme necessary for cholesterol synthesis. Binding to the active site of 
HMG-CoA reductase results in increased LDL receptor expression (Ward et al., 2019). A 
study by Xu Xiao and colleagues in 2013 has shown that, within the liver, inhibition of 
cholesterol synthesis results in the stimulation of sterol regulatory element binding proteins 
(SREBPs). SREBPs are translocated to the nucleus, upregulating LDL receptors and thus 
affect plasma cholesterol levels. Inhibition of cholesterol synthesis by statins, stimulates 
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SREBPs resulting in increased LDL uptake and decreased plasma cholesterol levels. This 
reduction in LDL by statins positively correlated with reducing the progression of ASCVD 
(Vaughan et al., 2000).  
 Although there are many different statins on the market whose dose dependent 
effects may differ, Weng and colleagues have shown that by modifying the dosage of 
statins to appropriate levels, all statins reduce LDL cholesterol levels in most patients. In 
particular, this thesis will focus on two specific statins: simvastatin and pitavastatin. 
Simvastatin was first approved in 1991 and developed by Merck, Sharp, and Dohme. Since 
then, it has been marketed by different companies in various countries under different 
brand names (Alzforum 2015). Simvastatin is primarily derived from fungal fermentation 
and has been shown to have high potency when compared to other statins. Pitavastatin is a 
more recently developed statin that was first approved in 2009 and developed in Japan by 
Nissan Chemical Industries and Kowa Pharmaceuticals. Despite its recent development, 
Pitavastatin has been found to be one of the more potent types of statins. Because of this, 
it is generally given in a lower dose (1, 2, or 4 mg) compared to statins such as simvastatin 
(20-40 mg) or pravastatin (40-80 mg) (NIDDK 2012). 
 Statins can be classified into two types, depending on their lipophilicity and 
physicochemical properties, hydrophilic or lipophilic. Although both types of statins have 
a similar effect on inhibiting HMG-CoA, the mechanisms by which they exert this effect 
differ. Hydrophilic statins require carrier-mediated uptake, exhibit greater 
hepatoselectivity and have less of an influence on smooth muscle proliferation (Schachter 
2005). However, the statins that will be highlighted in this thesis are lipophilic statins, 
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which passively diffuse through the hepatocellular membrane. Because of this property of 
lipophilic statins, studies have found that their hepatoselectivity is decreased because they  
are also able to diffuse in extrahepatic tissues (Shitara & Sugiyama 2006). This property 
could also explain the findings from meta-analyses and clinical trials involving statin 
therapy of a positive correlation with the development of new-onset diabetes when using 
lipophilic statins (Brault et al., 2014). When compared to hydrophilic statins, lipophilic 
statins such as simvastatin, seemed to negatively affect insulin sensitivity. 
Diabetes 
Diabetes is a major public health problem that has continued to grow and effects 
populations in both industrialized and developed countries around the world. According to 
the International Diabetes Federation, approximately 463 million adults (ages 20-79) were 
living with diabetes in 2019. The proportion of people with diabetes is increasing in most 
countries; with projections showing that the number of adults with diabetes will increase 
to 700 million by 2045 (IDF 2019).  
There are two main types of diabetes, Type 1 and Type 2. Type 1 Diabetes (T1D), 
is a result of the body’s immune system mistaking the insulin-producing β-cells as a foreign 
substance, thus attacking them and resulting in β-cell death. Type 2 Diabetes (T2D), which 
is more prevalent than T1D and has a more variable pathogenesis, stems from β-cell 
dysfunction and insulin resistance. Although both have different forms of pathogenesis, 
both types of diabetes are chronic diseases that affect our body’s ability to produce insulin, 
resulting in dysregulation of blood sugar levels. Recent studies have suggested that statin 
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therapy, in response to hypercholesterolemia, may impair insulin sensitivity and secretion 
based on clinical and epidemiologic studies (Laasko et al., 2017). However, the mechanism 
is not fully elucidated, and in vitro studies are necessary for gaining insights that can be 
valuable for clinical guidance. These studies have also demonstrated impaired insulin 
sensitivity and secretion (Scattolini et al., 2016). Because the development of 
cardiovascular disease is higher in patients with diabetes, additional in vitro studies are 
needed to further examine the relationship between statin use and diabetes. In this thesis, 
we investigate whether statins could alter metabolic regulation of normal glucose-induced 
insulin secretion (GSIS) in pancreatic β-cells. 
Insulin secretion and β-cell function 
Insulin is a peptide hormone secreted by pancreatic β-cells, and is a regulator of 
glucose homeostasis. Insulin is first made as its inactive precursor, preproinsulin. Through 
signal peptidases, the signal peptide on the N-terminus is removed, resulting in proinsulin. 
Through the removal of the C-peptide, proinsulin is then converted into the bioactive 
insulin hormone, where it is stored in secretory granules to be released from the β-cell. The 
β-cell releases insulin in response to stimuli such as circulating glucose and fatty acid (FA) 
in the blood. As glucose enters the blood, the β-cell responds through triggering and 
amplifying pathways that stimulate insulin release. 
The triggering pathway of insulin secretion begins when glucose enters the β-cell 
through the glucose transporter, GLUT1/GLUT2, where it is metabolized through 
glycolysis and mitochondrial respiration to produce ATP, increasing the ATP to ADP ratio. 
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This change in the ATP/ADP increases binding of ATP to the ATP-sensitive potassium 
(KATP) channel, resulting in the closure of this channel. The closure of the KATP channel 
results in a decrease of K+ permeability, causing membrane depolarization and the opening 
of voltage-dependent Ca2+ channels, triggering Ca2+ influx into the cell. An increase in the 
intracellular calcium ([Ca2+]i) stimulates insulin exocytosis by allowing insulin containing 
secretory granules to fuse with the plasma membrane and release their contents (Figure 1).  
The Ca2+-dependent triggering pathway of insulin secretion can be enhanced by the 
amplifying pathway of insulin secretion (Figure 2). Almost 20 years ago it was found that 
glucose continued to increase insulin release in a dose-dependent manner despite the use 
of diazoxide and KCl to prevent ATP-dependent closure of the KATP channel, while at the 
same time depolarizing the cell in order to increase [Ca2+]i  (Gembal et al., 1992). This 
seminal paper established that signals from glucose metabolism could enhance insulin 
exocytosis above Ca2+-induced triggering alone. Although amplification is dependent on 
the triggering signal, a study by Henquin found that stimulation of insulin secretion through 
the amplifying pathway occurs not only due to glucose but other non-glucose stimuli as 
well (Henquin , 2000). 
In addition to glucose, non-glucose stimuli such as FA are also acute stimulators of 
insulin secretion (Deeney et al., 2000). FA is converted inside the cell to its metabolically 
active CoA ester, Long-chain Acyl-CoA (LC-CoA). Sources of FA can be circulating in 
the serum outside the ß-cell or derived from intracellular stores such as triglyceride (TG) 
loaded lipid droplets. Circulating FA can potentially stimulate insulin secretion by binding 
to a GPR40 FA receptor on the ß-cell membrane coupled to activation of phospholipase C 
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(PLC) (Itoh et al., 2003). FA however does not need a receptor or transport protein to enter 
the cell. FA from outside the cell can enter the cell by passive diffusion (flip-flop) through 
the plasma membrane (Kamp & Hamilton, 1992). FA can also be derived from intracellular 
TG stores as a result of ß-cell lipolysis and can be oxidized for fuel or incorporated into 
lipids, some of which can be used for signal coupling to insulin exocytosis (Papackova & 
Cahova, 2015). Prior to oxidation or incorporation into lipids, FA must be converted to its 
metabolically active CoA ester, long-chain acyl CoA (LC-CoA). Prentki and Corkey in 
1996, found that increased production of malonyl-CoA through glucose metabolism 
inhibits FA oxidation and spares LC-CoA to be used in intracellular signaling and the 
stimulation of insulin release. This “Long-Chain Acyl-CoA Hypothesis” helps explain how 
LC-CoA can directly modulate enzymes and β-cell function involved in insulin exocytosis 
to potentiate glucose-stimulated insulin secretion (Prentki and Corkey, 1996; Corkey et al., 
2000). LC-CoA has been shown to activate the KATP channel decreasing the plasma 
membrane potential and lowering [Ca2+]i (Larsson et al., 1996). Using permeabilized ß-
cells it was also shown that LC-CoA could directly stimulate exocytosis through a putative 
protein acylation (Deeney, 2000).  
Furthermore, studies have shown that oscillations of [Ca2+]i and different metabolic 
variables such as oxygen consumption, NADPH, and ATP/ADP ratio, are associated with 
the oscillation frequencies of insulin secretion (Longo et al., 1991). Previously, it has been 
assumed that in single islets and pancreatic ß-cells, oscillations in insulin secretion were 
due solely to the oscillations in [Ca2+]i. In order to determine the main drivers of 
oscillations in insulin secretion, Cunningham found that when rat islets were perifused with 
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diazoxide and high KCl to induce and maintain high non-oscillatory levels of free [Ca2+]i, 
oscillations in glucose-stimulated insulin secretion still occurred with similar amplitude 
and frequency (Cunningham et al., 1996). Because of this, the mechanism for generating 
oscillations in insulin secretion is believed to involve both triggering and amplification 
pathways. 
 
Triggering    
Amplification   
Figure 1: Overview of glucose-stimulated insulin secretion triggering and amplifying 
pathway in the β-cell. Triggering Pathway — Glucose enters the cell through the GLUT-
1/GLUT-2 transporter, undergoing metabolism through both glycolytic and mitochondrial 
processes, in order to generate ATP. Because glucose fuels the generation of ATP, an 
increase in the ATP to ADP ratio develops. With an increased ATP to ADP ratio, the 
likelihood of ATP binding to the KATP channel increases, leading to the closure of the 
channel. The closure of the KATP channel results in decreased K+
 
permeability, causing 
membrane depolarization, which causes the activation of the voltage-dependent calcium 
channels (VDCC), allowing an influx of Ca2+. The increased amounts of Ca2+ entering 
through the VDCC stimulates insulin secretory granules to fuse with the membrane, thus 
triggering insulin secretion. Through the amplifying pathway―other metabolites such as 
LC-CoA and DAG, also have a role in the exocytosis of insulin granules through the 
activation of PKC.  
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Chronic Exposure to Excess Nutrients Left-Shifts Glucose-Stimulated Insulin 
Secretion 
Conditions in which β-cells are chronically exposed to excess glucose and FA, have 
been shown to result in glucolipotoxicity (GLT) (Saadeh et al., 2012). This condition is 
characterized by basal hypersecretion of insulin and impaired GSIS and was shown to be 
dependent on the concentration of FA. At low FA concentration basal insulin secretion was 
elevated, while higher concentrations decreased GSIS, as well. Thus, FA dose-dependently 
reduced the fold-increase in insulin secretion.  
Chronic exposure to excess nutrients (glucose and FA) causes TG accumulation 
leading to GLT in the β-cell. In the past researchers have added elevated levels of glucose 
and FA to the normal growth condition of ß-cells to study mechanisms of GLT. Perhaps 
surprisingly, historically the normal culture conditions for pancreatic islets and ß-cells was 
11 mM glucose with 10% fetal bovine serum (FBS). These conditions already amount to 
glucose that is twice normal human physiologic concentration and a high level of lipid 
derived from the added serum. These are conditions that already allow for accumulation of 
triglyceride (TG) containing lipid droplets and can impair ß-cell function. Thus, after 
adding additional excess nutrients researchers were often looking at advanced GLT rather 
than the mechanisms that may play a role in initiating such a GLT state. 
For this reason, our lab has examined the effects of culturing clonal INS-1 cells in 
lower glucose concentrations. INS-1 cells cultured in reduced glucose conditions (4 mM) 
accumulate much less lipid compared to cells cultured at 11 mM glucose (Erion, 2015). 
INS-1 cells cultured at 11 mM glucose exhibited a hypersensitivity to submaximal glucose 
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concentration when compared to INS-1 cells cultured at 4 mM glucose. A reduction in 
insulin secretion to maximum glucose conditions in the 11 mM glucose cultured cells was 
also observed (Figure 2). 
In order to explain this left-shift in GSIS, Erion and colleagues looked at whether 
Ca2+ influx was a factor. However, they found that the glucose-induced response in Ca2+ 
influx was similar across both the 4G and 11G cells. Rather it was determined that the left-
shifted glucose response was due to increased Ca2+ sensitivity of cells exposed to excess 
nutrients (11 mM glucose). 
 
 
Figure 2. Glucose-Stimulated Insulin Secretion of INS-1 Cells Chronically Grown 
in 4 mM and 11 mM conditions. Cells cultured at 11 mM glucose displayed 
hypersensitivity to submaximal glucose conditions, when compared to cells cultured at 
4 mM glucose. Also, cells cultured at 11 mM glucose showed a reduction in insulin 
secretion to maximal glucose conditions. Note: Figure 4A. INS-1 cells cultured in 
excess nutrients have a left-shifted insulin secretion glucose-dose response. Reprinted 
from Chronic Exposure to Excess Nutrients Left-shifts the Concentration Dependence 
of Glucose-stimulated Insulin Secretion in Pancreatic β-Cells (Erion 2015). 
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Mitochondrial Metabolism and Insulin Secretion 
 Through a series of processes within pancreatic β-cells, glucose is eventually 
metabolized to ATP. The ATP generated through the mitochondria can then act upon the 
KATP channels in the plasma membrane of the β-cell, leading to membrane depolarization, 
Ca2+ entry, and insulin exocytosis. As a result, the mitochondria of the β-cell, act as fuel 
sensors, generating products that allow for the coupling of nutrient metabolism to insulin 
exocytosis (Maechler & Wollheim, 2001).  
The β-cell mitochondria serve as the site in which complexes of the electron 
transport chain (ETC) pump protons from the mitochondrial matrix to the intermembrane 
space. Thus, a proton gradient is formed that allows for protein reentry, as well as fueling 
oxidative phosphorylation that occurs at complex V (F1F0 ATP Synthase). Before this can 
occur, oxygen is consumed at complex IV in response to proton extrusion. Because of this, 
the measurement of mitochondrial respiration through oxygen consumption, is oftentimes 
looked at as the most informative bioenergetic parameter, in order to determine normal 
function and flow of the ETC (Hynes 2006). Studies in our lab have shown that chronic 
exposure to excess nutrients leads to GLT, resulting in increased basal oxygen 
consumption. In the absence of an increase in ATP demand, excess nutrients generate 
mitochondrial hyperpolarization and excess reactive oxygen species (ROS) (Liesa & 
Shirihai, 2013). Increased production of ROS in the β-cell has been shown to increase 
insulin secretion, regardless of mitochondrial ATP synthesis (Pi et al., 2007). Over time, 
excess nutrients leading to the overproduction of ROS can cause mitochondrial damage. In 
order to control ROS-mediated toxicity due to excess nutrients, β-cell mitochondria have 
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been shown to have higher levels of proton leak (Affourtit & Brand, 2006). The mechanism 
of increased leak is still under investigation and may include contributions from increased 
fat oxidation and increased ATP demand as a result of increased protein synthesis (Rumala 
2019) as well as activation of ROS scavenging through nucleotide nicotinamide 
transhydrogenase (NNT). 
Cholesterol Affects Multiple Membrane Proteins that Contribute to Insulin Secretion 
 Cholesterol also plays an essential role in maintaining many of the body’s 
metabolic processes such producing hormones and bile, as well as helping to provide 
structure to cell membranes. Humans are able to produce approximately 700-900 mg of 
cholesterol per day. Cholesterol is produced through the liver as well as by most cells in 
the body. In addition to endogenous production, humans receive a portion of cholesterol 
from their dietary intake. This amount is typically between 300-500 mg per day. Studies 
have shown that we lose between 1-2 grams per day through processes such as 
desquamation, fecal loss, conversion to bile acids, and biosynthesis of hormones (Cox 
1990).  
Cholesterol contributes to biophysical properties of the membrane fluidity, 
curvature, and structure, all of which can affect function. Cholesterol has been shown to 
regulate signal transduction through membrane microdomains and is able to control gene 
expression through cholesterol-activated transcription factors (Brown & Goldstein, 1997). 
As a result, processes such as glucose metabolism can be affected through intracellular 
cholesterol and cholesterol-rich membrane microdomains. Studies have shown that there 
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may be a direct effect on GSIS from β-cells whose cellular membrane properties have been 
altered due to adjustment of cholesterol levels. A study by Xie and colleagues found that 
chronically inhibiting cholesterol biosynthesis resulted in marked reductions in voltage-
gated Ca2+ (CaV) currents and insulin secretion. Other studies have shown that elevated 
serum cholesterol reduced insulin secretion (Hao et al., 2007). In addition, brief exposure 
of INS-1 cells to β-methyl-cyclodextrin (MβCD) reduces cholesterol in the plasma 
membrane and stimulates GSIS (Xie et al., 2007). This shows that, GSIS is a process that 
may be sensitive to adjustments in cholesterol. 
Furthermore, cholesterol has also been shown to regulate the level of 
phosphatidylinositol 4,5-biphosphate (PIP2), which is an essential lipid that is involved in 
signal transduction and β-cell function. Cholesterol can affect the level of PIP2 by 
increasing its hydrolysis by phospholipase C (PLC) to produce the intracellular mediators, 
diacylglycerol (DAG) and inositol triphosphate (IP3), which contribute to insulin secretion. 
IP3 binds to its receptor inositol triphosphate receptor (IP3R), in the membrane of the 
endoplasmic reticulum (ER), releasing ER calcium and raising [Ca2+]i even further. DAG 
activates protein kinase C (PKC), which promotes exocytosis (Mancini & Poitout, 2013). 
DAG can also bind to Munc13 enhancing insulin exocytosis (Sheu et al., 2003). PIP2 
activates KATP channels, maintaining the channel open and counteracting the inhibitory 
effect of ATP (Xie et al., 2007). Studies have shown that cholesterol depletion, through 
hydrolysis of PIP2, results in an increase of plasma membrane Ca2+ influx from the 
extracellular space and IP3-stimulated calcium efflux from intracellular stores (Hao 2009). 
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This study also demonstrated that cholesterol has a key role in regulating PIP2 hydrolysis 
and the overall function of pancreatic β-cells. 
Statin Use and Increased Risk of Developing Diabetes 
In a recent study, Carmena (2019) revealed that there was about a 10-12% increased 
risk of new-onset diabetes (NOD) associated with statin therapy, when examining data 
from observational studies and meta-analyses of randomized clinical trials. Although the 
mechanism between statin use and insulin sensitivity has yet to be fully elucidated, various 
explanations have been proposed to explain its relationship.  
In a very detailed study, Brault and colleagues, have proposed three major 
mechanisms that could be responsible for this increased risk. The first is that certain statins 
decrease insulin secretion through reduced calcium channel activity in pancreatic β-cells, 
either directly, indirectly, or by a combined effect. Second, because statins competitively 
inhibit HMG-CoA, they also decrease important products downstream from the 
mevalonate pathway, such as Coenzyme Q (CoQ10), farnesyl pyrophosphate, and 
geranylgeranyl pyrophosphate, which play a crucial role in intracellular signaling. Third, 
statins may impede the translocation of glucose transporter 2 (GLUT 2) in response to 
statin exposure, resulting in hyperglycemia and hyperinsulinemia (Braut et al. 2014). A 
recent study by Urbano and colleagues found that certain lipophilic statins may affect both 
insulin release and mitochondrial metabolism, due to reduced production of CoQ10, a key 
component of electron transport in mitochondrial respiration, resulting in the suppression 
of antioxidant defense system and the introduction of reactive oxygen species (ROS) 




 This objective of this study was to compare the effect of two different types of 
statins: simvastatin and pitavastatin on insulin secretion and insulin content from pancreatic 
β-cells after chronic and acute exposure. We hypothesized that the Ca2+ influx that results 
from PIP2 hydrolization may vary between two different statin exposures, simvastatin and 
pitavastin. As a result, we investigated whether the oscillatory behavior of Ca2+ at low and 
high glucose differed between statins, leading to reduced insulin secretion. Furthermore, 
we aimed to investigate whether statins had an effect on mitochondrial respiration, 
affecting insulin secretion through altered ATP production.  
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METHODS AND MATERIALS 
Statin Preparation  
Simvastatin  
Simvastatin chemical structure contains a lactone(Figure 3); thus, before dilution in 
DMSO, simvastatin was first converted into its active form by dissolving 4 mg of 
simvastatin in 100 µL of ethanol. Afterwards, 150 µL of 0.1 N NaOH is added to the 
solution and incubated at 50º C for 2 hours. The pH is then adjusted to 7.0 using 0.1 N HCl. 







Pitavastatin structure (Figure 4) is that of a heptanoate as the basic structure, a core 
quinoline ring with Ca2+ at the center, and side chains that include both fluorophenyl and 
cyclopropyl (Saito 2011). Even though pitavastatin is not a lactone it was prepared the 
same way as simvastatin, but at a stock concentration of 10 mM since it yields two 
molecular species when in solution. Statins were further diluted in dimethyl sulfoxide 
(DMSO) to working stocks of 200 µM simvastatin and 100 µM pitavastatin and stored at 
-80ºC.  
Statins were added to appropriate culture media by dilution the working stock 1000-fold 
to a final concentration of 200, 100, 50, 25 nM. Concentrations were achieved by serial 
dilution with 0.1 % DMSO serving as the no statin control. Cells were incubated with 





INS-1 Cell Culture  
 All experiments in this study were conducted using clonal pancreatic INS-1 832/13 
(Hohmeier et al., 2000). These cells were grown in either 4 mM or 11 mM glucose in 
Roswell Park Memorial Institute (RPMI 1640) media containing 10 mM 4-(2-
HydroxylEthyl)-1 Piperazine Ethane Sulfate (HEPES), 2 mM glutamine, 1 mM pyruvate, 
50 IU/mL penicillin, 50 µg/mL streptomycin, 10% Fetal Bovine Serum (FBS), and 50 µM 
β-mercaptoethanol (BME). Cells were passaged once a week to continue to carry the cell 
line and to grow cells in multi-well plates for experiments. Cells were used between 
passage 58 and 72. 
 Cells that were to be used in experiments were typically plated into 48-well plates 
(Corning, NY) to reach approximately 240,000-250,000 cells/well on the day secretion was 
performed. The cell number seeded in these wells was based on the doubling time, which 
was 33 hours in 11 mM glucose media, and 56 hours in 4 mM glucose media. 
 Cells were typically grown two days before chronic exposure with two different 
types of statins: pitavastatin or simvastatin, for three days. Control cells were given DMSO 
for three days. Afterwards, cells were ready for glucose-stimulated insulin secretion (GSIS) 




Insulin secretion   
 After the chosen exposure times to statins, INS-1 cells were then ready for GSIS 
experiments. Cells were first examined and counted to ensure that intended cell growth 
was reached and to account for any cell loss. Growth conditions were first removed and 
replaced by a condition of 1 mM glucose RPMI, containing 10 mM HEPES, 2 mM 
glutamine, and 1 mM pyruvate (1G RPMI), and incubated for 2 hrs. After the 2-hrs 
incubation period, the 1G RPMI was removed and cells were then pre-incubated with 
Krebs-Ringer Bicarbonate Buffer (KRB) containing 119 mM NaCl, 4.6 mM KCl, 5 mM 
NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 0.15 mM NaHPO4, 0.4 mM KH2PO4, 20 mM 
HEPES, 1 mM glucose, and 0.05% fatty acid free bovine serum albumin (BSA) (Sigma, 
St. Louis, MO), pH 7.4 (1G KRB) at 37ºC for 30 minutes. After 30 minutes of exposure to 
1 G KRB, cells were placed on ice for 5 minutes. After 5 minutes on ice, 1G KRB was 
removed and replaced with test conditions. 
 Initially, the glucose dose-responses of INS-1 cells were measured to ensure that 
cells were responding properly. In this case, test solutions of KRB containing 1, 2, 3, 4, 6, 
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Cells ready for 
GSIS experiment
Figure 5. Timeline of INS-1 cells passaged for GSIS experiments
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and 8 mM glucose were added to cells. Next, the effect of chronic statin treatment was 
tested. In this case, cells were exposed to statin for three days prior to testing secretion. 
GSIS from control cells not exposed to statin were tested at 1 and 12 mM glucose, in order 
to demonstrate normal cell responsiveness. Statin conditions were tested at 12 mM glucose. 
Cells were then incubated in test solutions in a 37º water bath for an additional 2 hrs and 
then cooled on ice for 5 min. Finally, samples were removed and added to equal volume 
of KRB with 1% BSA in a 96well plate. The diluted samples were then centrifuged for 3 
minutes at 4000 RPM at 4º C to separate any cells that may have been collected. Finally, 
after being spun down a portion of each insulin sample was collected and transferred to a 
new well and frozen at -20º C.  
Insulin Content 
In order to determine insulin content, two wells from each condition of the 48-well 
plate were incubated with 500 µL/well trypsin (0.05%) for 5 minutes, until cells became 
rounded. These cells were then combined according to the condition and collected into 1.5 
mL Eppendorf tubes and placed on ice in order to deactivate the effects of trypsin. Cells 
from each condition were then counted using a hemocytometer to account for any changes 
in cell growth conditions. 
Afterwards, the rest of the cells were centrifuged at 4000 RPM for 3 minutes to 
aspirate the trypsin and collect the pellet. The pellet was then lysed using 150 µL of 
phosphate-buffered saline (PBS) solution containing 0.1% Triton X-100 (Sigma, St. Louis, 
MO) and 25 mM NaOH. The tubes were then placed on ice for 15 minutes. Afterwards, 
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150 µL of KRB with 1% BSA was added to each Eppendorf. All samples were stored at -
20º C and assays were performed after appropriate dilution. 
Insulin Assay 
 Insulin was measured using a FRET-based HTFR assay kit from Cisbio. This kit 
contains two antibodies with separate fluorescent tags attached. When both antibodies bind 
with insulin a fluorescence resonance energy transfer (FRET) signal is measured. No signal 
is produced from free antibody or an antibody that is bound without the other on the same 
insulin molecule. The assay was performed as follows: 2 µL of each sample was collected 
and placed in a well on a 1536 well plate, which was then spun down for 10 seconds using 
a centrifuge at 4000 RPM at 4º C. Similarly, 2 µL of the antibody was then placed on top 
of each sample and spun down once again. The assay plate was sealed and incubated 
overnight in a humidified chamber. Assay fluorescence was measured using a Tecan 
Infinite M 1000 PRO spectrophotometer (excitation/emission: 317/620 nm). The ratio of 
the FRET signal over the total signal was used to determine insulin concentration, after 
comparing samples to a standard curve. All results were exported to and calculated using 
Microsoft Excel. Test assays of the low and high glucose samples were conducted to 





Mitochondrial Respiration Measurement 
Seahorse XFe96 cell culture microplates were coated using 50 µg/mL poly-d-lysine 
for 1 hour. Poly-d-lysine was removed and the plated was washed four times with sterile 
water before cells were seeded. Cells were plated at varying densities depending on the 
number of days of culture prior to the experiments. The final density of cells was 
approximately 60,000 cells/well for cells cultured at either 4 mM or 11 mM glucose. The 
night before the experiment the Agilent Seahorse XFe96 Sensor Cartridges was hydrated 
by and placing the sensor cartridge into the utility plate containing 200 µL of XF Calibrant 
solution. The assembled sensor cartridge and utility plate were placed in a non-CO2 
incubator overnight.  
On the day of the experiment, growth conditions were first removed from the cells 
and replaced with 1G RPMI. Cells on the four corners of the Seahorse plate were removed 
using trypsin to be used for cell counting and as background wells during the measurement. 
The Seahorse plate was then incubated for 1 hr at 37ºC without CO2. After the 1 hr 
incubation period, 1G RPMI was removed and and replaced with 1G KRB for 30 minutes. 
Immediately before the experiment, the buffer was changed to fresh 1G KRB.  
Just prior to the experiment the sensor cartridge was loaded with test solutions and 
calibrants to be injected onto the cells at times programmed for the particular experiment. 
Glucose in Port A, and the calibrants oligomycin in Port B, carbonyl cyanide-p-
triflouromethoxyphenylhydrazone (FFCP) in Port C, and antimycin in Port D. Test 
solutions and calibrants were injected as 10X solutions, which after dilution reached final 
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concentrations of 11 mM glucose, 5 µM oligomycin, 2.5 µM FCCP and 10 µM antimycin. 
The sensor and cell plate were then loaded into the XFe96 Seahorse machine to measure 
oxygen consumption rate (OCR). The number of measurements and timing for each 
condition are found within the experimental figure. 
Calcium Activity Measurement  
Cells were plated in 35-mm glass bottom dishes coated with 20 µM poly-D-lysine 
at a seeding density of about 10,000 cells for 11 mM glucose growth conditions and 20,000 
cells for 4 mM glucose. Statin incubations were similar to that described for secretion 
above with only the highest concentration of 200 nM tested. On the day of the experiment, 
growth conditions were first removed and replaced by 1G RPMI and incubated for 1 hr. 
After 1 hr, cells were incubated with 2 µM fura-2 AM (Invitrogen, Carlsbad, CA) with 
0.1% pluronic acid (Thermo Fisher Scientific) for 30 min at 37ºC. Then, fura-2 AM 
solution was removed and cells were pre-incubated with 1G KRB for 30 min. Immediately 
before the experiment, fresh 1G KRB was added to the cells.  
Images were captured using an Olympus DSU spinning disk confocal microscope 
at 20X magnification at 37º C. Basal measurements were recorded for 10 minutes and were 
followed by a perifusion of higher glucose 3 mM and 12 mM for 15 minutes each. KCl 
was perifused during the last five minutes to ensure normal cellular response. Fluorescence 
was measured every 20 seconds at two separate excitation wavelengths (340nm and 380 
nm) and emission at 510 nm was collected from each wavelength. Data was analyzed using 
Nikon Cell Sense software. Approximately 80-100 cells were zoned in a square within the 
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center of the image and single cells were selected at random (Figure 6). Single cell calcium 
data was then exported to excel, where it was color coded on a spectrum to determine 
calcium intensity and to identify any unresponsive cells. Imaging was done in the DOM 





GSIS from INS-1 cells Cultured in High Glucose (11mM) 
INS-1 cells were cultured in 11 mM glucose for five days before GSIS experiments 
were performed. Cells were acutely exposed to one of the following conditions: 1 mM, 2 
mM, 4 mM, 6 mM and 8 mM glucose and insulin secretion was measured. As the glucose 
concentrations increased, respective increases in insulin secretion were also observed 
(Figure 7). Slight increases in insulin secretion were observed at both 2 mM and 4 mM 
glucose. The greatest change in secretion was observed between the 4 mM and 6 mM 
glucose test conditions.  
 
Figure 7. GSIS of INS-1 cells cultured in 11 mM glucose. INS-1 cells were 
cultured in 11 mM glucose for 5 days and increasing glucose conditions were 
introduced: 1 mM, 2mM, 4 mM, 6 mM, and 8 mM glucose. Insulin secretion 
was measured after 2 hours of incubation in the different conditions. There was 
a statistically significant difference at both 6 mM and 8 mM glucose conditions 



























Overall, in Figure 7, basal secretion was observed to be 15.5 ng/106 cells at 1 mM 
glucose and increased to 96.2 ng/106 cells at 8 mM glucose. An approximate 6-fold 
increase was observed between these conditions. Although multiple experiments yielded 
different numbers for insulin secretion, the fold-change in secretion was always greater 
than 3 and the sigmoidal trend was always observed.  
Effects of Simvastatin on GSIS and Insulin Content from INS-1 Cells Cultured at 11 
mM Glucose 
INS-1 cells were cultured in 11 mM glucose for 5 days. After 2 days of growth, 
cells were switched to 11 mM glucose media containing different concentrations of 
simvastatin (0-200 nM) and incubated for three more days. Insulin secretion was measured 
from control cells stimulated with both 1 mM and 12 mM glucose to demonstrate glucose 
responsiveness. The difference in insulin secretion between the two groups was nearly 5-
fold (Figure 8A). The effects of varying concentrations of simvastatin were measured only 
at 12 mM glucose.  
 Inhibition of insulin secretion by simvastatin was concentration dependent (Figure 
8B). Simvastatin inhibition was significant at 100 nM and 200 nM when compared to 
control and was 19% and 39% respectively. Because the decrease in insulin secretion may 
have been a result of decreased total insulin in the cell or impaired exocytosis, insulin 
content was also measured.  
 Simvastatin significantly decreased insulin content in INS-1 cell cultured at 11 mM 
glucose in a concentration dependent manner (Figure 9A). At each concentration of statin 
(25 nM, 50 nM, 100 nM, and 200 nM) insulin content was reduced by 25%, 21%, 50%, 
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and 54%, respectively (Figure 9A). Secretion was then plotted as percent content to adjust 
for this loss (Figure 9B). Insulin secretion was normalized, with increased secretion 
observed at 100 nM and 200 nM, 76% and 34%, respectively. Correction for insulin content 
is a way for testing whether exocytosis itself is impaired. Since insulin secretion as percent 
total insulin content was not inhibited by simvastatin, the decrease in insulin secretion 









Figure 8. Insulin Secretion of INS-1 cells grown in 11 mM glucose exposed to 1 
mM and 12 mM glucose (A) and simvastatin inhibited GSIS when exposed to 
the highest concentration of statin (B). INS-1 cells were cultured in 11 mM 
glucose for 5 days. After 2 days, simvastatin at four different concentrations (25 nM, 
50 nM, 100 nM, and 200 nM), was added to the cells for 3 days. Cells were then 
exposed to 12 mM glucose and incubated for 2 hours. There was a statistically 
significant difference at 200 nM as determined by one-way ANOVA (*, p<.05). 






Figure 9. Simvastatin reduced insulin content (A) and increased adjusted insulin 
secretion at 100 nM and 200 nM from figure 12B measured in units of percent 
content (B). At each dose of statin, a statistically significant difference for insulin 
content (A) was observed. Insulin secretion corrected for percent content (B) at 100 nM 
and 200 nM had a significant increase. Statistically significant differences were 
determined by one-way ANOVA (*, p<.05). Error bars represent ± SE. 
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Effects of Pitavastatin on Insulin Secretion and Content from INS-1 Cells Cultured 
at 11 mM Glucose 
INS-1 cells were grown in 11 mM glucose for 5 days. Pitavastatin (0-200 nM) was 
added to the cells for the last 3 days of culture.  Insulin secretion was measured as described 
for simvastatin. The difference in insulin secretion between 1 mM basal glucose and 12 
mM stimulatory glucose was nearly 5-fold (Figure 10A).  
 Pitavastatin did not significantly inhibit insulin secretion at any of the 
concentrations tested, although there was a tendency for pitavastatin to reduce GSIS at the 
highest concentration (200 nM) (Figure 10B).  
 Unlike the results of insulin secretion, pitavastatin significantly decreased insulin 
content over the concentration range tested (Figure 11A). Pitavastatin decreased insulin 
content by 24%, 26%, and 35% at 50, 100 and 200 nM concentration respectively. 
Although a decrease in insulin content was observed, when representing the data as percent 
content, no statistically significant differences were observed in any of the pitavastatin 






Figure 10. Insulin Secretion of INS-1 cells grown in 11 mM glucose exposed to 1 
mM and 12 mM glucose (A) and pitavastatin showed no inhibitory effect on GSIS 
when exposed to different concentrations (B). INS-1 cells were cultured in 11 mM 
glucose for 5 days. After 2 days, pitavastatin at four different concentrations (25 nM, 
50 nM, 100 nM, and 200 nM), was added to the cells for 3 days. Cells were then exposed 
to 12 mM glucose and incubated for 2 hours. There was no statistically significant 
difference at any statin condition as determined by one-way ANOVA (*, p<.05). Error 







Figure 11. Pitavastatin reduced insulin content (A) and but had no effect on 
adjusted insulin secretion from figure 12B measured in units of percent content 
(B). At 50 nM, 100 nM, and 200 nM a statistically significant difference for insulin 
content (A) was observed. Insulin secretion corrected for percent content (B) had no 
statistically significant difference at any dose of pitavastatin. Statistically significant 




Effect of Simvastatin and Pitavastatin on Average Intracellular Ca2+ Activity in 
INS-1 Cells  
INS-1 Cells were grown in 35 mm glass bottom dishes for 4 days in 11 mM glucose. 
After 1 day of growth, media was switched to 11 mM glucose media containing 200 nM 
of pitavastatin or simvastatin. On the day of the experiment, fura-2 was used to compare 
Ca2+ handling of control and statin treated cells. Cells were exposed to 1 mM glucose for 
10 minutes and then switched to 3 mM and 12 mM glucose for 15 minutes each, followed 
by 5 minutes of KCl to show that the cells were responsive. Results were recorded using 
Nikon Cell Sense software. Single cell Ca2+ data was exported to excel in order to calculate 
the average fura ratio from 30-40 cells selected randomly for each condition.  
  Figure 12 shows the average [Ca2+]i, from INS-1 cells cultured in 11 mM glucose 
(A) vs 4 mM glucose (B) and comparing the effects of simvastatin and pitavastatin (200 
nM each) to control. The number of averaged cells was 32 for cells cultured at 11 mM and 
40 cells cultured at 4 mM glucose. Cells cultured at 11 mM glucose exhibited an average 
fura ratio at 1 mM basal glucose of 0.6, while the average for cells cultured at 4 mM glucose 
was 0.52 (Figure 12 A vs B). Simvastatin and pitavastatin both increased this average basal 
in cells cultured in 11 mM glucose to 0.65 (A). Average basal in cells cultured in 4 mM 
glucose was increased to 0.6 and 0.62 with simvastatin and pitavastatin respectively (B).  
Cells exposed to simvastatin revealed fura ratio oscillations with increased 
frequency and larger amplitude, when compared to control at 1 mM, 3 mM, and 12 mM 
glucose. (A) Although the [Ca2+]i average was higher, the frequency and amplitude in 
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oscillations for the cells exposed to pitavastatin was not different than control at 1 mM, 3 






























































1 mM Glucose 3 mM Glucose 12 mM Glucose KCl
Figure 12. Averaged activities of intracellular Ca2+ in INS-1 Cells grown in 11 mM 
(A) and 4 mM (B) glucose exposed to Simvastatin (200 nM) and Pitavastatin (200 
nM). Cells were cultured for 4 days and incubated in their respective statins for 3 days. 
Cells were stimulated in 1 mM glucose for 10 minutes, glucose was then raised to 3 
mM and 12 mM glucose for 15 minutes each and then exposed to KCl for 5 minutes.  
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Effect of Simvastatin and Pitavastatin on Intracellular Ca2+ Activity from single 
INS-1 Cells  
Individual traces of random cells were obtained to provide a better representation 
of statin effects. The results from the individual traces provide a clearer depiction of single 
cell responses to the different conditions of statins when exposed to varying levels of 
glucose. Fura ratios were also color coded on a spectrum to measure cell calcium intensity 
and oscillatory behavior (Figure 13). Each column represents a single cell and each row 
represents a time point that is 20 seconds apart from the next.  
 First, we will compare the control cells not treated with statin. 11 mM cultured cells 
exhibit a fairly even distribution of green and red time points over the different acute 
glucose exposures (1, 3 and 12 mM).  This is in stark contrast to cells cultured at 4 mM 
glucose, which exhibit little [Ca2+]i activity at 1 and 3 mM glucose and have a sizable 
increase in activity when glucose is increased to 12 mM. The continuous red section at the 
bottom of each trace represents addition of 30 mM KCl. These data correlate well to the 
fact that secretion from cells cultured at high glucose is left-shifted compared to cells 
cultured at low physiological glucose level. 
Pitavastatin increases the baseline fura ratio in a number of cells compared to the 
control. This can be seen as increased number of cell columns that are green throughout 
the entire time course compared to control cells that have green but more often than not 
return to a lower ratio indicated by blue. This increase in the basal fura ratio is dramatic in 





cell. Pitavastatin treatment only slightly increased the oscillatory pattern compared to 
control cells in both cells cultured at 11 and 4 mM glucose.  
Simvastatin has a more potent effect on both cells cultured at 11 and 4 mM glucose 
compared to pitavastatin. Oscillations are increased in the cells cultured at 11 mM glucose 
at all acute glucose concentrations tested (1, 3 and 12 mM). Even more obvious is the clear 
increase in oscillatory activity of cells cultured at 4 mM glucose and acutely stimulated 
with 3 mM glucose. The effect of Simvastatin on cells cultured at 4 mM glucose is to 
induce glucose hypersensitivity, thus left-shifting the glucose response in terms of Ca2+ 
influx.  
These same results can be visualized by plotting line graphs for the individual cells 
to be plotted on top of each other. Fura ratios from cells cultured in 11 mM glucose and 
treated without statin or with 200 nM each of pitavastatin and simvastatin is shown in 
Figure 14. Here it is seen that the oscillatory behavior of these cells is such that the 
oscillations appear at all glucose concentrations tested (1, 3 and 12 mM). Control cells 
appear not to be sensitive to any glucose concentration that is more stimulatory than basal. 
Pitavastatin and simvastatin increase oscillations in these cells at 3 and 12 mM glucose 
concentrations.   
Fura ratios from cells cultured in 4 mM glucose and treated without statin or with 
200 nM each of pitavastatin and simvastatin is shown in Figure 15. Here it is seen that the 
oscillatory behavior of these cells is such that the oscillations appear only at the highest 
glucose concentration tested (12 mM). Control cells appear not to be sensitive to 1 and 3 
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Figure 14. Individual intracellular Ca2+ traces of 40 cells cultured in 11 mM 
glucose simvastatin and pitavastatin. Both control and pitavastatin cells have an 
increased response at 12 mM glucose. Cells exposed to simvastatin have an 
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Figure 15. Individual intracellular Ca2+ traces of 40 cells cultured in 4 mM 
glucose simvastatin and pitavastatin. Both control and pitavastatin cells have an 
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at 3 mM glucose concentration. Pitavastatin was much less potent at inducing oscillatory 
activity at 3 mM glucose concentration.   
Effect of Simvastatin and Pitavastatin to recruit single INS-1 Cells to Oscillate 
We next determined the number of cells recruited by simvastatin and pitavastatin 
to exhibit oscillations in [Ca2+]i. In cells cultured at high glucose there were a large number 
of control cells not treated with statin that exhibited Ca2+ oscillations at low glucose (1 and 
3 mM) (Figure 16A). The percentage of oscillating cells in this case was 62.5% and 
increased in both pitavastatin and simvastatin groups (75% and 78%, respectively). At 12 
mM glucose, Ca2+ response was approximately 80% across each group.  
In cells cultured at low glucose, a small number of control cells not treated with 
statin that exhibited Ca2+ oscillations at low glucose (1 and 3 mM) (Figure 16B). The 
percentage of oscillating cells in this case was 6.25% and was increased in cells exposed 
to pitavastatin and simvastatin. In contrast to cell cultured at high glucose, both pitavastatin 
and simvastatin significantly increased the number of cells that showed Ca2+ oscillations 
when acute glucose was increased from 1 to 3 mM glucose. In the pitavastatin group, the 
percentage of cells that were recruited went from 0% at 1 mM glucose to 21.9% at 3 mM 
glucose. Similarly, in the simvastatin group, the percentage of cells that were recruited 
greatly increased from 18.75% at 1 mM glucose to 84% at 3 mM glucose. At 12 mM 







Effect of Simvastatin and Pitavastatin on Mitochondrial Respiration in INS-1 Cells  
 INS-1 cells were grown in seahorse XFe96 cell culture microplates for 4 days. After 
1 day of growth, media was switched to media containing different concentrations of 
simvastatin. On the day of the experiment, sensors were loaded with four different 
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Figure 16. Effect of statin conditions on recruitment of cells that exhibit a Ca
2+
 
response at 1 and 3 mM glucose concentrations in INS-1 cells grown in 11 mM (A) and 
4 mM (B) glucose. Data are expressed as means ± SE. Total number of cells under 





















with 12 mM glucose, Port B was loaded with 5 µM oligomycin, Port C was loaded with 
2.5 µM FCCP, and Port D was loaded with 10 µM antimycin. Oligomycin, FCCP, and 
antimycin were added to determine respiration due to ATP production, maximal respiration 
indicating spare respiratory capacity and minimal respiration, which along with oligomycin 
indicates proton leak. Results were observed in real time and are presented for cells 
cultured at high 11 mM glucose (Figure 17) and low 4 mM glucose (Figure 18).  
Control cells cultured at 11 mM glucose had more than twice the basal respiratory 
rate compared with cells cultured at 4 mM glucose. Increasing glucose from 1 mM to 12 
mM increased respiration to a lesser extent in cells cultured at 11 mM glucose compared 
to cells cultured at 4 mM glucose (30% vs 50%). In cells cultured at high glucose, 
respiration due to ATP production, spare respiratory capacity and proton leak were all 
twice the level of cells cultured at low glucose.  
Simvastatin did not significantly affect respiration in cells cultured at high glucose, 
at any metabolic state during the course of the experiment. In particular there was no 
indication of simvastatin increasing production of ATP in these cells. In contrast high 
concentrations of simvastatin (100-200 nM) tended to increase basal respiration, 
respiration due to ATP production, spare respiratory capacity and proton leak in cells 
cultured at low glucose. These increases were statistically significant for proton leak and 







Figure 17. Oxygen consumption rate (OCR) of INS-1 mitochondria cultured in 11 
mM glucose and different doses of simvastatin (A) and oxygen consumption rate 
of each condition after performing a stress test (B). OCR at basal remained relatively 
constant at each condition. The 50 nM simvastatin condition had a decrease in OCR 
when spare respiratory capacity was observed. Statistically significant differences were 






























































Figure 18. Oxygen consumption rate (OCR) of INS-1 mitochondria cultured in 4 
mM glucose and different doses of simvastatin (A) and oxygen consumption rate 
of each condition after performing a stress test (B). OCR at basal remained relatively 
the same, with a significant difference observed at 50 nM simvastatin. Simvastatin at 
50 nM, 100 nM, and 200 nM, have increased OCR after undergoing stress conditions. 
Statistically significant differences were determined by one-way ANOVA (*, p<.05). 
































































 In recent years, more studies have reported that increased duration of statin use for 
the prevention of cardiovascular disease (CVD), is associated with an increased risk of 
developing Type 2 Diabetes (T2D). As a result, mechanistic studies explored the 
relationship between statins and their effect on the β-cell. In this study, we validated 
previous results from our lab demonstrating that statins reduce both GSIS and insulin 
content from clonal pancreatic β-cells. The inhibitory effect of simvastatin was greater and 
over a lower concentration range (50-200 nM) than for pitavastatin, which mostly inhibited 
at the highest concentration tested (200 nM). Reduced GSIS was not explained by impaired 
Ca2+ influx induced by the statins. In fact, chronic statin treatment (200 nM) increased the 
number of cells that exhibited calcium oscillations in our experiments. Interestingly, 
simvastatin had a greater effect on Ca2+ oscillatory behavior than pitavastatin and the 
effects were more obvious in cells cultured at low glucose (4 mM) compared to high 
glucose (11 mM).  Preliminary results suggest that simvastatin increased respiration 
driving ATP synthesis in cells cultured in 4 mM glucose, which can potentially explain the 
effect of simvastatin on Ca2+ influx. These results may point to an early effect of statin to 
stimulate hypersecretion at low glucose concentration, which then over time decreases 
insulin content and GSIS. 
 INS-1 cells that were chronically cultured in 11 mM glucose and exposed to 
simvastatin for three days, resulted in a dose-dependent reduction in insulin secretion. 
Similarly, insulin content also decreased in a dose-dependent manner. When expressed as 
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percent content, these findings suggest that the reduction in GSIS is a result of diminished 
insulin content rather than impaired insulin exocytosis. It has been previously reported that 
ß-cells exposed to high glucose and excess FA also over time become depleted of insulin 
content (Rhodes 1985). In this case it was proposed that the loss of content was due to FA 
stimulating hypersecretion of insulin without a concomitant increase in insulin synthesis. 
Although inducing a dose-dependent decrease in insulin content, pitavastatin significantly 
inhibited GSIS only at high concentration and when corrected for insulin content, 
pitavastatin stimulated insulin secretion at low concentration. It is not known whether 
longer statin incubations would have made the effects of simvastatin and pitavastatin on 
secretion more similar. The effect of pitavastatin to increase insulin secretion when 
analyzed as percent insulin content could provide insight into how insulin content is lost in 
ß-cells over time. The greater inhibition of GSIS by simvastatin compared to pitavastatin 
is in agreement with previous findings in our lab and other studies that found the use of 
lipophilic statins resulted in significant decreases in insulin secretion when compared to 
hydrophilic statins (Aiman 2014).  
In order to determine potential mechanisms of statin effects on insulin secretion, we 
examined the effects of simvastatin and pitavastatin on [Ca2+]i. As previously noted, an 
increase in [Ca2+]i stimulates insulin release. Comparing Ca2+ responses from cells cultured 
at both 11 and 4 mM glucose and treated with no statin, treatment with 200 nM simvastatin 
or 200 nM pitavastatin increased resting [Ca2+]i as well as oscillations in [Ca2+]i in INS-1 
cells. Cells with no statin treatment cultured in 11 mM glucose exhibited a higher average 
resting [Ca2+]i than cells cultured at 4 mM glucose. This is consistent with an increased 
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oxygen consumption rate in cells cultured at higher glucose concentration (Rumala 2020). 
For this reason the average increase in resting [Ca2+]i after statin exposure was less obvious 
in cells chronically exposed to high glucose.  
Average [Ca2+]i oscillation amplitude and frequency detected in cells cultured at high 
glucose was similar over the glucose range tested. This was in contrast to cell cultured at 
low glucose, which exhibited no oscillatory behavior until 12 mM glucose was added. 
These results confirm results of Yuhan Qiu (Qiu 2019) and are consistent with the fact that 
1 and 3 mM glucose do not stimulate insulin release in cells cultured at low glucose (Erion 
et al., 2015). For this reason the effect of statins to increase average [Ca2+]i oscillations was 
less obvious in cells cultured at high glucose compared to low glucose cultured cells. In 
cells cultured at low glucose, simvastatin increased oscillations in average [Ca2+]i when 
glucose was increased from 1 to 3 mM. Pitavastatin did not increase [Ca2+]i oscillations 
under the same conditions. 
These results were more noticeable when examining the individual traces of the thirty 
randomized cells for each condition. Examination of individual responses also 
demonstrated that average increases in [Ca2+]I were not due to increased amplitude or 
frequency of oscillations but rather an increase in the number of cells recruited to oscillate. 
Interestingly, our lab has previously demonstrated that increasing glucose concentration in 
ß-cells also increases the average [Ca2+]i by recruiting cells to oscillate rather than affecting 
oscillation amplitude or frequency (Heart & Corkey, 2006).  
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These results are from cells, that were pre-exposed to statin. As with our secretion 
experiments, statin was then removed at least two hrs prior the Ca2+ measurement. Our 
novel observation is that statin can increase the sensitivity of the ß-cell to glucose and that 
this effect is more pronounced in cells cultured at low 4mM glucose. In our experiments 
Simvastatin was more potent than pitavastatin in producing this hypersensitivity. The left-
shift in glucose sensitivity leading to increased [Ca2+]i oscillations highlights potential 
metabolic regulation of the pm  by the cholesterol lowering statin compounds. Cholesterol 
in the plasma membrane may indirectly affect the KATP channel and pm. Cholesterol 
depletion has been shown to stimulate the hydrolysis of PIP2 and GSIS (Hao 2007). A 
reduction in PIP2 decreases its ability to bind and inhibit the KATP channel (Schulze 2003). 
This increased ATP sensitivity of the KATP channel results in increased closure of the 
channel and membrane depolarization leading to increased Ca2+ influx. Our results 
demonstrate the effect of statins on Ca2+ oscillations warrants an investigation of the effects 
of statin on membrane potential directly. Although cholesterol depletion and an increase in 
Ca2+ are known to increase insulin secretion, these results were not reflected within our 
glucose-stimulated insulin secretion experiments. However, this may be due to statin 
exposure causing acute hypersecretion of insulin that may lead to β-cell dysfunction and 
diminished secretion of insulin over time (Cantley and Ashcroft 2015).  
 Because previous studies have found that simvastatin may inhibit mitochondrial 
function in β-cells (Curry et al. 2019), we looked to determine if the inhibition of insulin 
secretion may be due to impaired mitochondrial respiration. However, our findings suggest 
that in cells chronically grown in 11 mM glucose, there is no effect of simvastatin on 
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mitochondrial respiration. However, cells grown in 4 mM glucose, showed an increase in 
ATP production, proton leak, and spare respiratory capacity, following exposure to 
simvastatin.  
Similarly, there was a trending increase in cells grown in 11 mM glucose. The lack 
of effect of simvastatin on cells cultured in high glucose could likely be due to these cells 
already having increased oxygen consumption compared to cells cultured at more normal 
physiologic glucose. Previous studies have shown increased mitochondria fragmentation 
from cells grown in excess nutrients, together with increased maximal respiratory rates and 
proton leak (Liessa & Shirihai, 2013). Although the mechanism isn’t completely 
understood, this study suggests that mitochondrial fragmentation may contribute to cristae 
remodeling causing an increased import of nutrients and promotion of proton leak. 
Furthermore, in the absence of an increase in ATP demand, excess nutrients generate 
mitochondrial hyperpolarization and excess ROS.  Over time, excess nutrients leading to 
the overproduction of ROS can cause mitochondrial damage. In order to control ROS-
mediated toxicity due to excess nutrients, β-cell mitochondria have been shown to have 
higher levels of proton leak. This also supports current literature that has shown that under 
GLT conditions mimicking T2D, associated mutations resulting in the impairment of the 
nicotinamide nucleotide transhydrogenase (NNT) gene, resulted in poorer glucose 
tolerance and decreased energy efficiency (Parker et al. 2009). NNT is a mitochondrial 
inner membrane protein that couples proton translocation to a redox reaction reducing 
mitochondrial NADP+ while oxidizing NADH and is involved in the detoxification of ROS 
(Rydstrom et al. 1970). Because of the higher proton leak, ATP production, and spare 
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respiratory capacity, statins may play a role in mitochondrial fragmentation or NNT 
dysfunction. 
 Thus, we hypothesize that a potential mechanism for impaired insulin secretion and 
increased risk of T2D due to statin treatment could be insulin hypersecretion at low 
stimulatory glucose concentration which depletes insulin stores and impairs GSIS over 
time. This hypersecretion could be driven by recruitment of ß-cells exhibiting oscillations 
in Ca2+ influx. In our model system, pitavastatin was less potent than simvastatin in causing 
this change in ß-cell Ca2+ handling. If the proposed mechanism proves valid, pitavastatin 
may be a better therapeutic choice than simvastatin to lower cholesterol as it may have less 
risk for stimulating insulin hypersecretion leading to later impaired GSIS. Future 
experiments need to assess the effects of statins on basal insulin secretion in our cell model 
and further on isolated human islets/ß-cells.  
 Because our experiments demonstrate an effect of simvastatin on Ca2+ response and 
mitochondrial respiration at low glucose, future studies need to examine changes in GSIS 
through the effect of statins on cells cultured at low glucose. The tests we have performed 
indicate that cells exposed to simvastatin may alter glucose sensitivity and exhibit an effect 
similar to that of excess nutrients. Furthermore, the effect of simvastatin on increasing Ca2+ 
at low glucose indicates a need to investigate basal insulin secretion as a contributing factor 
to hyperinsulinemia. Nonetheless, more experiments measuring oxygen consumption and 
Ca2+ response need to be done to provide a more representative view of statins effect on 
the β-cell.  
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